For the NSCLC cohort, 85% patients had adenocarcinoma with programmed death-ligand 1(PD-L1) tumor proportion score (TPS), a standard prognostic biomarker for patients with NSCLC) [20]. The gene discussed is CD274; the disease is adenocarcinoma.